Genprex Unveils Promising Lung Cancer Therapy and Strategic Partnership at AACR 2026

Genprex, Inc., a clinical-stage gene therapy company, presents new findings and strategic partnerships that significantly enhance its potential impact on lung cancer treatment. At the 2026 American Association for Cancer Research, Genprex reveals promising preclinical results regarding its lead drug candidate, Reqorsa® Gene Therapy, which targets lung cancers resistant to existing therapies.

Genprex Unveils Promising Findings at AACR Annual Meeting

Genprex emphasizes its ongoing dedication to innovative cancer treatments, as highlighted by its presentation at the AACR Annual Meeting. According to its CEO, Ryan Confer, Reqorsa demonstrates effectiveness on ALK-EML4 positive non-small cell lung cancer (NSCLC) cell lines, showcasing its contribution to decreasing tumor volume and inducing apoptosis. Specifically, results indicate Reqorsa’s capacity to augment Natural Killer (NK) cells' activity, not only suppressing tumors but also achieving complete elimination in some cases during preclinical trials.

Furthermore, the research identifies TROP2 and PTEN biomarkers that could predict patient resistance to Reqorsa therapy. This discovery sets a foundation for improved patient selection in upcoming clinical trials aimed at realizing a more personalized approach for lung cancer patients facing treatment challenges. The findings, which derive from advanced models including organoids and patient-derived xenografts, signal a potential shift in lung cancer treatment paradigms.

Collaboration with MD Anderson Cancer Center

In conjunction with its research breakthroughs, Genprex announces a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center, aimed at further exploring the TROP2 and PTEN biomarkers. This partnership, part of an ongoing collaboration since 2010, is geared toward enhancing individualized treatment strategies for lung cancer patients, especially those who have unmet medical needs.

Significant Steps Forward in Tailored Cancer Therapies

Ryan Confer expresses enthusiasm about the implications of these biomarkers for Genprex’s clinical trials, specifically the Acclaim-1 and Acclaim-3 trials. Acclaim-1 is currently enrolling patients in its Phase 1/2 stage, focusing on the combination of Reqorsa and AstraZeneca's Tagrisso® (osimertinib) for late-stage NSCLC patients. This underscores Genprex's commitment to pioneering tailored therapies that address the complexities of lung cancer treatment.

Through these advancements, Genprex aims to not only improve therapeutic efficacy but also enhance the clinical outcomes for lung cancer patients, fundamentally changing the landscape of treatment options available.